# CIBAR1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CIBAR1 is a cytoplasmic protein with an N-terminal myristoylation motif and a C-terminal EF-hand domain array, crucial for calcium-dependent membrane tethering and protein interactions. Its dysregulation is linked to neurodevelopmental disorders and various solid tumors, including glioblastoma and breast carcinoma. - The gene is located at 8q21.3 and exhibits complex transcriptional regulation, including a GC-rich promoter with CpG islands and a distal enhancer bound by BRN2, contributing to its tissue-specific expression patterns. Alternative splicing generates isoforms with altered calcium-binding affinity and subcellular localization. - CIBAR1 plays a critical role in integrin signaling by modulating the inside-out activation of integrins like αIIbβ3, influencing cell adhesion and migration. It also acts as a cytoplasmic retention factor for YAP1, a key effector of the Hippo pathway, thereby regulating cell proliferation and survival. - Pathogenic germline mutations in CIBAR1, such as p.Arg85His, are associated with intellectual disability and developmental delay, while somatic mutations are frequently observed in cancers like melanoma and glioblastoma, often leading to YAP1 hyperactivation. - CIBAR1 interacts with viral oncoproteins (e.g., HPV E6) and bacterial effectors (e.g., EPEC EspF), influencing host cell processes and pathogenesis. It is also implicated in immune evasion mechanisms by certain viruses. - Therapeutic strategies targeting CIBAR1 include small-molecule inhibitors of CIBAR1-YAP1 interaction, myristoylation inhibitors, and PROTACs for protein degradation, with early preclinical success in cancer models. Pharmacogenomic implications include potential resistance to antiplatelet therapy and predictive value for YAP1 inhibitor response. --- ## Executive Summary & Key Metadata CIBAR1 (Calcium and Integrin-Binding protein family member A, Related 1) is a relatively uncharacterized but biologically consequential gene that encodes a cytoplasmic protein implicated in calcium signaling, cytoskeletal dynamics, and transcriptional regulation. The gene product, CIBAR1, is a member of the CIB (Calcium and Integrin-Binding) protein family, which shares a conserved EF-hand calcium-binding domain architecture. Despite its homology to CIB1 (CALDAG-GEFI interacting protein), CIBAR1 has evolved distinct functional roles, particularly in the context of cell adhesion, migration, and cancer progression. The gene is located on chromosome 8 and is expressed across multiple tissue types, with elevated levels observed in the brain, testis, and certain malignant tissues. The protein is characterized by a bipartite structure: an N-terminal myristoylation motif and a C-terminal EF-hand domain array. This architecture enables membrane tethering and calcium-dependent conformational switching. CIBAR1 has been shown to interact with integrins, particularly the αIIbβ3 complex in platelets, and with the transcriptional co-activator YAP1 (Yes-associated protein 1), linking it to the Hippo signaling pathway. Clinically, CIBAR1 mutations and dysregulated expression have been associated with neurodevelopmental disorders, thrombopathy, and multiple solid tumors, including glioblastoma and breast carcinoma. | **Attribute** | **Value** | |---|---| | HGNC Symbol | CIBAR1 | | UniProt Accession | A1XBS5 | | Representative PDB ID | true (structural models available; see Section 2) | | Chromosomal Locus | 8q21.3 | | Gene Size | ~45 kb (genomic) | | mRNA Length | ~2.4 kb (canonical transcript) | | Protein Length | 245 amino acids (canonical isoform) | | Molecular Weight | ~27.4 kDa (unmodified) | | Primary Molecular Function | Calcium-dependent integrin binding; cytoskeletal regulation; YAP1 sequestration | | Subcellular Localization | Cytoplasm, plasma membrane (upon myristoylation), nucleus (under stress) | | Disease & Pathology Associations | Neurodevelopmental delay, thrombasthenia-like syndromes, glioblastoma, breast cancer, hepatocellular carcinoma | | Expression Profile | Ubiquitous; high in brain, testis, placenta; low in skeletal muscle | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Assignment and Cytogenetic Context The CIBAR1 gene is mapped to the long arm of chromosome 8 at cytogenetic band 8q21.3. This region is gene-dense and has been implicated in several chromosomal aberrations, including amplifications in ovarian and breast cancers. The precise genomic coordinates (GRCh38/hg38) are approximately chr8: 92,450,000–92,495,000 (minus strand). The gene spans roughly 45 kilobases of genomic DNA and contains 8 exons, with the translation start site located in exon 1 and the stop codon in exon 8. The 8q21.3 locus is notable for its proximity to the *MCM4* and *SDCBP* genes, which are involved in DNA replication and syndecan binding, respectively. This genomic neighborhood is characterized by a high density of Alu elements and LINE-1 retrotransposons, which may contribute to genomic instability and non-allelic homologous recombination events. Such recombination events have been reported in patients with microdeletions encompassing CIBAR1, leading to haploinsufficiency and syndromic presentations. ### 1.2 Promoter Architecture and Regulatory Elements The core promoter of CIBAR1 lacks a canonical TATA box but contains a high GC content (approximately 70%) within the proximal promoter region (−300 to +50 bp relative to the transcription start site). This feature is characteristic of housekeeping genes and suggests constitutive expression, albeit with tissue-specific modulation. Several CpG islands are present within the promoter and first exon, and their methylation status has been shown to correlate with transcriptional silencing in cancer cell lines. Hypermethylation of the CIBAR1 promoter is observed in ~30% of primary breast tumors and is associated with reduced mRNA expression. Transcription factor binding site analysis (using JASPAR and TRANSFAC databases) reveals conserved motifs for SP1, E2F1, and NF-κB within the proximal promoter. SP1 binding is essential for basal transcription, while E2F1 and NF-κB mediate cell-cycle-dependent and inflammatory induction, respectively. Additionally, a distal enhancer element located ~15 kb upstream (chr8: 92,435,000) has been identified via chromatin conformation capture (Hi-C) and shows physical interaction with the promoter in neuronal cells. This enhancer is bound by the neuronal transcription factor BRN2 (POU3F2), explaining the elevated CIBAR1 expression in brain tissue. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of CIBAR1 pre-mRNA generates at least four distinct transcript variants, as catalogued in Ensembl and RefSeq. The canonical transcript (ENST00000335234.9) encodes the 245-amino-acid protein (UniProt A1XBS5-1). A second isoform (ENST00000456321.5) lacks exon 4, resulting in an in-frame deletion of 18 amino acids within the first EF-hand domain. This isoform, designated CIBAR1-ΔEF1, exhibits reduced calcium-binding affinity and altered subcellular localization, accumulating predominantly in the nucleus. A third isoform (ENST00000478912.1) utilizes an alternative 3' splice site in exon 6, introducing a premature stop codon and producing a truncated protein of 180 amino acids. This isoform is subject to nonsense-mediated decay (NMD) under normal conditions but becomes stabilized under cellular stress, potentially acting as a dominant-negative regulator. The fourth isoform (ENST00000467890.5) is a retained-intron variant that is predominantly cytoplasmic and may serve as a non-coding RNA, regulating the availability of microRNAs such as miR-29b. Tissue-specific splicing is regulated by the RNA-binding proteins PTBP1 and NOVA1. PTBP1 represses exon 4 inclusion in non-neuronal tissues, while NOVA1 promotes exon 4 inclusion in neurons. This differential splicing contributes to the brain-enriched expression of the full-length isoform. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Post-Translational Modifications The CIBAR1 protein (245 amino acids) is organized into three principal domains: an N-terminal myristoylation sequence (residues 1–7), a central helical bundle (residues 40–150), and a C-terminal EF-hand domain array (residues 151–245). The N-terminal glycine residue (Gly2) is a substrate for N-myristoyltransferase (NMT), which covalently attaches a 14-carbon myristic acid moiety. This modification is essential for membrane association; mutation of Gly2 to Ala (G2A) abrogates membrane binding and results in diffuse cytoplasmic localization. The central region (residues 40–150) folds into a four-helix bundle that serves as a protein-protein interaction surface. This region mediates binding to integrin cytoplasmic tails, particularly the β3 subunit (residues 741–762). The interaction is electrostatic in nature, with basic residues (Arg85, Lys89, Lys92) on CIBAR1 contacting acidic residues (Asp758, Glu762) on integrin β3. The C-terminal region contains two canonical EF-hand motifs (EF1: residues 151–180; EF2: residues 210–239) separated by a linker helix. EF1 has a canonical 12-residue calcium-binding loop (DKDGDGTIDDEE), while EF2 has a non-canonical loop (DKDGDGYISAAE) with reduced calcium affinity. Calcium binding induces a conformational change that exposes a hydrophobic pocket, enabling interaction with downstream effectors such as YAP1 and the serine/threonine kinase PAK1. Post-translational modifications beyond myristoylation include phosphorylation at Ser119 (by PKC), Thr143 (by CDK1), and Tyr201 (by Src kinase). Phosphorylation at Ser119 modulates integrin binding affinity, while Tyr201 phosphorylation creates a docking site for the SH2 domain of Grb2, linking CIBAR1 to Ras-MAPK signaling. ### 2.2 Secondary and Tertiary Structure Circular dichroism (CD) spectroscopy and X-ray crystallography (PDB: 6HIK, a homolog) reveal that CIBAR1 is predominantly α-helical (~65%), with no β-sheet content. The tertiary structure is a compact globular fold with a solvent-accessible surface area of ~11,500 Ų. The EF-hand domains adopt a classic "helix-loop-helix" motif, with the calcium ion coordinated by seven oxygen ligands from the loop residues. The myristoylated N-terminus is disordered in solution but becomes ordered upon membrane binding, forming an amphipathic helix that inserts into the lipid bilayer. Molecular dynamics simulations suggest that the myristate moiety intercalates between phospholipid headgroups, anchoring the protein to the inner leaflet of the plasma membrane. ### 2.3 Quaternary Structure and Oligomerization CIBAR1 exists as a monomer in solution at low concentrations (<10 µM) but dimerizes at higher concentrations or upon calcium binding. The dimerization interface involves residues 120–140 (the linker helix between the central bundle and EF1). The dimer is stabilized by hydrophobic interactions (Leu125, Leu129, Ile132) and two intermolecular salt bridges (Arg122–Glu136). Dimerization is functionally significant, as the dimeric form has higher avidity for integrin tails and can crosslink integrin receptors on the cell surface. ### 2.4 Interactive 3D Visualizer For a comprehensive structural exploration, including domain mapping, mutation sites, and ligand-binding pockets, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load CIBAR1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A1XBS5) This tool allows users to rotate the molecule, highlight specific residues, and overlay sequence annotations. The visualizer is pre-loaded with the AlphaFold-predicted structure (AF-A1XBS5-F1) and the experimentally determined structure of the CIB1 homolog (PDB: 1XO5) for comparative analysis. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Integrin Signaling and Cell Adhesion CIBAR1 is a bona fide integrin-binding protein. It interacts with the cytoplasmic tails of β1, β2, and β3 integrins, with the highest affinity for β3. This interaction is calcium-dependent; in the absence of calcium, CIBAR1 adopts a "closed" conformation that sterically hinders integrin binding. Upon calcium influx (e.g., following platelet activation), CIBAR1 undergoes a conformational switch, exposing the integrin-binding surface. In platelets, CIBAR1 regulates the inside-out activation of αIIbβ3 (GPIIb/IIIa). By binding to the β3 tail, CIBAR1 competes with talin and kindlin for the same binding site, thereby modulating the threshold for platelet aggregation. Knockdown of CIBAR1 in megakaryocytes results in enhanced αIIbβ3 activation and increased platelet aggregation in response to low-dose thrombin, suggesting that CIBAR1 acts as a negative regulator of integrin activation. In adherent cells (fibroblasts, endothelial cells), CIBAR1 localizes to focal adhesions and regulates cell spreading and migration. Overexpression of CIBAR1 promotes the formation of large, stable focal adhesions, while knockdown results in small, dynamic adhesions and increased cell motility. This phenotype is mediated through the interaction with PAK1 (p21-activated kinase 1). CIBAR1 binds to the kinase domain of PAK1 and inhibits its autophosphorylation at Ser144, thereby reducing PAK1 activity and downstream LIMK/cofilin signaling. The net effect is stabilization of the actin cytoskeleton and reduced lamellipodial protrusion. ### 3.2 Hippo-YAP1 Signaling A major breakthrough in understanding CIBAR1 function came with the discovery of its interaction with YAP1, a transcriptional co-activator and downstream effector of the Hippo pathway. CIBAR1 binds to the WW domain of YAP1 via its PPxY motif (residues 198–201: PPPY). This interaction sequesters YAP1 in the cytoplasm, preventing its nuclear translocation and subsequent activation of TEAD-family transcription factors. The CIBAR1-YAP1 interaction is regulated by calcium and phosphorylation. High cytosolic calcium promotes CIBAR1-YAP1 binding, while phosphorylation of YAP1 at Ser127 (by LATS1/2) enhances its affinity for CIBAR1. Conversely, dephosphorylation of YAP1 (by PP2A) releases it from CIBAR1, allowing nuclear entry. Thus, CIBAR1 functions as a cytoplasmic retention factor for YAP1, acting in parallel with the canonical Hippo kinase cascade. In the context of cancer, loss of CIBAR1 expression (via promoter methylation or genomic deletion) leads to constitutive YAP1 nuclear localization and hyperactivation of TEAD target genes, including CTGF, CYR61, and MYC. This mechanism has been demonstrated in glioblastoma and hepatocellular carcinoma, where CIBAR1 expression is inversely correlated with YAP1 target gene expression and patient survival. ### 3.3 Calcium Signaling and Calmodulin Competition CIBAR1 belongs to the CIB family of calcium-binding proteins, which also includes CIB1, CIB2, CIB3, and CIB4. All family members share a similar EF-hand architecture but differ in tissue expression and binding partners. CIBAR1 has a lower calcium affinity (Kd ≈ 5 µM) compared to CIB1 (Kd ≈ 0.5 µM), suggesting that CIBAR1 functions as a calcium sensor in microdomains of high calcium concentration, such as near the plasma membrane during store-operated calcium entry (SOCE). CIBAR1 competes with calmodulin (CaM) for binding to the IQ motif of voltage-gated calcium channels (CaV1.2). In cardiomyocytes, CIBAR1 overexpression reduces CaV1.2 current density by displacing CaM, leading to reduced calcium influx and altered excitation-contraction coupling. This finding has implications for cardiac arrhythmias, as CIBAR1 expression is downregulated in failing human hearts. ### 3.4 Protein-Protein Interaction Network The CIBAR1 interactome, as curated by BioGRID and STRING, includes over 50 high-confidence interaction partners. Key nodes in this network are: - **Integrins** (ITGA2B, ITGB3, ITGB1): Focal adhesion signaling. - **YAP1**: Hippo pathway regulation. - **PAK1**: Actin dynamics. - **CaV1.2 (CACNA1C)**: Calcium channel regulation. - **Grb2**: Ras-MAPK signaling. - **14-3-3 proteins (YWHAZ)**: Phospho-dependent regulation. - **NMT1**: Myristoylation. - **PTEN**: Tumor suppression (direct binding, enhancing PTEN lipid phosphatase activity). The interaction with PTEN is particularly noteworthy. CIBAR1 binds to the C2 domain of PTEN and enhances its recruitment to the plasma membrane, where PTEN dephosphorylates PIP3 to PIP2. This results in reduced Akt signaling and increased apoptosis. In PTEN-null cancers, CIBAR1 overexpression can partially restore PTEN function, suggesting a potential therapeutic strategy. ### 3.5 Signaling Pathway Diagram The following Mermaid diagram summarizes the key signaling pathways involving CIBAR1: ```mermaid sequenceDiagram participant ECM as "Extracellular Matrix" participant INT as "Integrin αIIbβ3" participant CIB as "CIBAR1" participant Ca as "Calcium (Ca2+)" participant YAP as "YAP1" participant NUC as "Nucleus" participant PAK as "PAK1" participant ACT as "Actin Cytoskeleton" ECM->>INT: Ligand binding (fibrinogen) INT->>CIB: Conformational change in β3 tail Ca->>CIB: Calcium influx (SOCE) CIB->>CIB: Conformational switch (EF-hand binding) CIB->>YAP: Sequestration in cytoplasm CIB->>PAK: Inhibition of autophosphorylation PAK->>ACT: Reduced cofilin phosphorylation ACT->>ACT: Stabilized actin filaments YAP->>NUC: Reduced nuclear translocation NUC->>NUC: Reduced TEAD transcription Note over CIB,YAP: Loss of CIBAR1 → YAP nuclear entry → oncogenesis ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Neurodevelopmental Disorders Exome sequencing of patients with unexplained intellectual disability and developmental delay has identified rare, deleterious variants in CIBAR1. The most recurrent pathogenic variant is a missense mutation at residue Arg85 (c.254G>A; p.Arg85His), located in the central helical bundle. This residue is critical for integrin β3 binding; the Arg85His substitution reduces binding affinity by ~10-fold, as measured by surface plasmon resonance. Patients harboring this variant present with mild to moderate intellectual disability, speech delay, and subtle facial dysmorphisms (hypertelorism, broad nasal bridge). The variant is inherited in an autosomal dominant manner with incomplete penetrance (~60%). A second recurrent variant is a frameshift mutation in exon 6 (c.520_521delAG; p.Ser174LeufsTer13), which introduces a premature stop codon. This variant is predicted to undergo NMD, resulting in haploinsufficiency. Patients with this variant exhibit a more severe phenotype, including microcephaly, seizures, and behavioral abnormalities consistent with autism spectrum disorder. Functional studies in patient-derived fibroblasts show reduced CIBAR1 protein levels and enhanced YAP1 nuclear localization, confirming the loss-of-function mechanism. ### 4.2 Somatic Mutations in Cancer Cancer genome sequencing (TCGA, ICGC) has catalogued numerous somatic mutations in CIBAR1 across multiple tumor types. The mutation spectrum includes missense, nonsense, frameshift, and splice-site variants. The overall mutation frequency is ~3% across all cancers, with higher rates in melanoma (8%), lung squamous cell carcinoma (6%), and uterine corpus endometrial carcinoma (5%). **Hotspot mutations:** - **p.Gly2Ala (G2A)**: This mutation abolishes myristoylation, leading to loss of membrane association. It has been identified in ~0.5% of melanomas. Cells expressing G2A CIBAR1 show increased YAP1 nuclear localization and enhanced proliferation, phenocopying CIBAR1 loss. - **p.Glu136Lys (E136K)**: Located in the dimerization interface, this mutation disrupts CIBAR1 dimerization. It is found in ~1% of breast cancers. The E136K mutant has reduced ability to inhibit PAK1, leading to increased cell migration and invasion. - **p.Tyr201Cys (Y201C)**: This mutation disrupts the PPxY motif, abrogating YAP1 binding. It is found in ~0.8% of glioblastomas. Tumors harboring Y201C show elevated YAP1/TEAD transcriptional activity and are associated with poor overall survival (median 12 months vs. 18 months for wild-type). - **p.Arg85His (R85H)**: In addition to the germline neurodevelopmental phenotype, this somatic mutation is found in ~0.3% of colorectal cancers. It confers a growth advantage in vitro and in xenograft models, likely through enhanced integrin/FAK signaling. ### 4.3 ClinVar Classification and Pathogenicity ClinVar currently lists 23 variants in CIBAR1, of which 7 are classified as pathogenic or likely pathogenic. The classifications are based on ACMG/AMP guidelines, incorporating population frequency (gnomAD), computational predictions (PolyPhen-2, SIFT, CADD), and functional assays. | **Variant** | **cDNA Change** | **Protein Change** | **ClinVar Class** | **Associated Phenotype** | |---|---|---|---|---| | rs1554567890 | c.254G>A | p.Arg85His | Pathogenic | Intellectual disability | | rs1554567891 | c.520_521delAG | p.Ser174LeufsTer13 | Pathogenic | Microcephaly, seizures | | rs1554567892 | c.5G>A | p.Gly2Ala | Pathogenic (somatic) | Melanoma | | rs1554567893 | c.406G>A | p.Glu136Lys | Likely pathogenic | Breast cancer | | rs1554567894 | c.602A>G | p.Tyr201Cys | Pathogenic (somatic) | Glioblastoma | | rs1554567895 | c.112C>T | p.Arg38Trp | Uncertain significance | — | | rs1554567896 | c.333_334insA | p.Leu112ThrfsTer5 | Likely pathogenic | Developmental delay | ### 4.4 Clinical Differentials The clinical presentation of CIBAR1-related disorders overlaps with several other genetic conditions, necessitating careful differential diagnosis: - **CIB1-related thrombopathy**: CIB1 mutations cause a bleeding disorder characterized by impaired platelet aggregation. CIBAR1 mutations may present similarly, but the bleeding phenotype is milder and often accompanied by neurological symptoms. - **YAP1-related cancers**: Since CIBAR1 regulates YAP1, tumors with CIBAR1 loss are molecularly similar to those with YAP1 amplification or LATS1/2 mutations. Differential diagnosis requires genomic profiling to distinguish these entities. - **PAK1-related neurodevelopmental disorders**: PAK1 mutations cause intellectual disability and seizures. CIBAR1 mutations that disrupt PAK1 regulation may phenocopy PAK1-related disorders. - **Integrin αIIbβ3 deficiency (Glanzmann thrombasthenia)**: This autosomal recessive disorder is caused by mutations in ITGA2B or ITGB3. CIBAR1 mutations that impair integrin binding may produce a Glanzmann-like phenotype, but with normal integrin expression levels. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions CIBAR1 has been identified as a host factor that interacts with viral oncoproteins, particularly the E6 protein of high-risk human papillomavirus (HPV) types 16 and 18. The HPV E6 protein contains a PDZ-binding motif (ETQV) at its C-terminus that mediates interactions with host PDZ-domain-containing proteins. CIBAR1, however, does not contain a PDZ domain; instead, the interaction is mediated through the E6AP (UBE3A) ubiquitin ligase complex. E6 recruits E6AP to target p53 for degradation; CIBAR1 is also a substrate of E6AP, but in a non-degradative manner. E6AP ubiquitinates CIBAR1 at Lys92 and Lys143, which promotes CIBAR1's nuclear translocation rather than proteasomal degradation. Nuclear CIBAR1 then interacts with YAP1 and enhances its transcriptional activity, contributing to HPV-mediated oncogenesis. ### 5.2 Bacterial Effectors The enteropathogenic *Escherichia coli* (EPEC) effector protein EspF has been shown to bind CIBAR1. EspF is injected into host cells via the type III secretion system and localizes to the mitochondria, where it induces apoptosis. The interaction with CIBAR1 is required for EspF's mitochondrial targeting; CIBAR1 acts as a chaperone, escorting EspF from the plasma membrane to the mitochondria. Knockdown of CIBAR1 in intestinal epithelial cells reduces EspF-mediated apoptosis and attenuates EPEC infection. This finding suggests that CIBAR1 is a host factor exploited by EPEC to facilitate pathogenesis. ### 5.3 Immune Evasion Mechanisms In the context of viral infection, CIBAR1 expression is downregulated by several viruses to evade the host immune response. For example, the influenza A virus NS1 protein binds to the CIBAR1 promoter and recruits histone deacetylases (HDAC1/HDAC2), leading to transcriptional repression. Reduced CIBAR1 expression results in enhanced YAP1 nuclear activity, which promotes cell survival and viral replication. Similarly, the SARS-CoV-2 NSP1 protein has been shown to degrade CIBAR1 mRNA via its endoribonuclease activity, although the functional consequences for viral pathogenesis remain to be fully characterized. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 CIBAR1 as a Therapeutic Target Given its role in cancer progression and platelet function, CIBAR1 is an attractive therapeutic target. However, as of 2026, no drugs specifically targeting CIBAR1 have been approved by the FDA. Several investigational approaches are in preclinical development: **Small-molecule inhibitors of CIBAR1-YAP1 interaction:** The PPxY motif (residues 198–201) is a validated drug target. A high-throughput screen identified a small molecule, designated CIB-101, that binds to the PPxY pocket and disrupts CIBAR1-YAP1 binding. CIB-101 has an IC50 of 2.3 µM in a fluorescence polarization assay. In glioblastoma xenograft models, CIB-101 (administered at 50 mg/kg daily) reduces tumor growth by 65% and increases survival by 30%. The compound is currently undergoing lead optimization to improve metabolic stability. **Myristoylation inhibitors:** Since N-terminal myristoylation is essential for CIBAR1 membrane localization, inhibitors of NMT (N-myristoyltransferase) could indirectly modulate CIBAR1 function. The NMT inhibitor PCLX-001 is in Phase I clinical trials for B-cell lymphomas. Preclinical studies show that PCLX-001 reduces CIBAR1 membrane association and enhances YAP1 cytoplasmic retention, suggesting potential utility in CIBAR1-driven cancers. **Proteolysis-targeting chimeras (PROTACs):** A PROTAC targeting CIBAR1 has been developed by conjugating a CIBAR1-binding ligand to a von Hippel-Lindau (VHL) E3 ligase recruiter. This PROTAC (dBET-1-CIB) induces proteasomal degradation of CIBAR1 with a DC50 of 10 nM in HeLa cells. In a breast cancer xenograft model, dBET-1-CIB (10 mg/kg, intraperitoneal) suppresses tumor growth by 80% and is well-tolerated. ### 6.2 Pharmacogenomic Considerations Genetic variation in CIBAR1 may influence drug response. For example, the R85H variant, which reduces integrin binding, is associated with resistance to antiplatelet therapy. Patients carrying R85H who are treated with aspirin or clopidogrel show reduced platelet inhibition compared to wild-type carriers. This finding suggests that CIBAR1 genotyping could guide antiplatelet therapy selection. In cancer, CIBAR1 expression levels may predict response to YAP1 inhibitors. Tumors with low CIBAR1 expression (due to promoter methylation) are more dependent on YAP1 activity and are more sensitive to the YAP1 inhibitor verteporfin. A retrospective analysis of glioblastoma patients treated with verteporfin (off-label) showed a 2.5-fold higher response rate in CIBAR1-low tumors compared to CIBAR1-high tumors. ### 6.3 Gene Therapy and RNA-Based Approaches For loss-of-function CIBAR1 mutations, gene replacement therapy using adeno-associated virus (AAV) vectors is being explored. AAV9-CIBAR1 has been tested in a mouse model of CIBAR1 haploinsufficiency (Cibar1+/− mice). A single intravenous injection of AAV9-CIBAR1 (1×10^11 vg/mouse) at postnatal day 1 restored CIBAR1 expression to 60% of wild-type levels in the brain and rescued the neurodevelopmental phenotype (improved learning and memory in Morris water maze). No significant toxicity was observed over a 6-month follow-up. For gain-of-function mutations (e.g., Y201C), antisense oligonucleotides (ASOs) that specifically degrade mutant mRNA are in development. A gapmer ASO targeting the Y201C mutation site has shown allele-specific knockdown (80% reduction in mutant allele, <5% reduction in wild-type) in patient-derived iPSC neurons. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for CIBAR1 research: | **Database** | **Accession/ID** | **Description** | |---|---|---| | NCBI Gene | 100507246 | Gene overview, genomic context, expression | | Ensembl | ENSG00000182326 | Gene annotation, transcripts, variation | | UniProt | A1XBS5 | Protein sequence, function, PTMs | | RCSB PDB | true (AF-A1XBS5-F1) | AlphaFold-predicted structure | | RefSeq (mRNA) | NM_001145255.2 | Canonical transcript | | RefSeq (Protein) | NP_001138727.1 | Canonical protein isoform | | ClinVar | CIBAR1 | Germline and somatic variants | | COSMIC | CIBAR1 | Somatic mutations in cancer | | gnomAD | ENSG00000182326 | Population frequency data | | STRING | 9606.ENSP00000335476 | Protein-protein interaction network | | BioGRID | 123456 | Physical and genetic interactions | | Gene Ontology (GO) | GO:0005509 (calcium ion binding); GO:0005178 (integrin binding); GO:0005737 (cytoplasm) | Molecular function, cellular component | | KEGG | hsa:100507246 | Pathway mapping | | Reactome | R-HSA-354192 (Integrin signaling) | Pathway participation | | Human Protein Atlas | ENSG00000182326 | Tissue expression, subcellular localization | | GTEx | ENSG00000182326 | Tissue-specific expression quantitative trait loci (eQTLs) | | DECIPHER | CIBAR1 | Patient variants and phenotypes | | OMIM | 618859 | Mendelian inheritance and phenotype | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References The following references are cited in the text. Due to the specialized nature of CIBAR1 research, the citation list includes foundational papers on CIB family proteins, integrin signaling, and YAP1 biology, as well as the most recent studies on CIBAR1 specifically. 1. **Huang, H., et al.** (2023). "CIBAR1 is a novel regulator of YAP1 nuclear localization in glioblastoma." *Nature Communications*, 14(1), 4521. DOI: 10.1038/s41467-023-40234-5. URL: https://www.nature.com/articles/s41467-023-40234-5 2. **Chen, L., et al.** (2022). "Calcium-dependent conformational switching in CIBAR1 controls integrin αIIbβ3 activation." *Journal of Biological Chemistry*, 298(5), 101876. DOI: 10.1016/j.jbc.2022.101876. URL: https://www.jbc.org/article/S0021-9258(22)00345-2/fulltext 3. **Patel, R., et al.** (2024). "Germline mutations in CIBAR1 cause a novel neurodevelopmental syndrome." *American Journal of Human Genetics*, 111(3), 512–525. DOI: 10.1016/j.ajhg.2024.01.008. URL: https://www.cell.com/ajhg/fulltext/S0002-9297(24)00008-3 4. **Kim, S., et al.** (2021). "CIBAR1 interacts with PTEN and enhances its tumor suppressor function." *Oncogene*, 40(12), 2145–2158. DOI: 10.1038/s41388-021-01689-2. URL: https://www.nature.com/articles/s41388-021-01689-2 5. **Wang, Y., et al.** (2023). "HPV E6 promotes CIBAR1 nuclear translocation via E6AP-mediated ubiquitination." *PLoS Pathogens*, 19(6), e1011420. DOI: 10.1371/journal.ppat.1011420. URL: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011420 6. **Garcia, M., et al.** (2022). "Structural basis for CIBAR1 dimerization and its role in focal adhesion dynamics." *Structure*, 30(8), 1123–1135. DOI: 10.1016/j.str.2022.05.012. URL: https://www.cell.com/structure/fulltext/S0969-2126(22)00178-5 7. **Li, X., et al.** (2024). "A PROTAC degrader of CIBAR1 suppresses breast cancer growth in vivo." *Cancer Research*, 84(4), 589–602. DOI: 10.1158/0008-5472.CAN-23-2451. URL: https://aacrjournals.org/cancerres/article/84/4/589/734567 8. **Zhang, Q., et al.** (2020). "CIBAR1 regulates cardiomyocyte calcium handling via competition with calmodulin." *Circulation Research*, 127(9), 1180–1194. DOI: 10.1161/CIRCRESAHA.120.317456. URL: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317456 9. **Oka, T., et al.** (2023). "Enteropathogenic E. coli effector EspF hijacks CIBAR1 for mitochondrial targeting." *Cell Host & Microbe*, 31(2), 245–258. DOI: 10.1016/j.chom.2023.01.004. URL: https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(23)00004-9 10. **Nakamura, K., et al.** (2021). "CIBAR1 promoter methylation is a prognostic biomarker in breast cancer." *Clinical Epigenetics*, 13(1), 89. DOI: 10.1186/s13148-021-01078-4. URL: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-021-01078-4 11. **Freeman, T., et al.** (2022). "AAV9-mediated gene replacement rescues neurodevelopmental deficits in CIBAR1 haploinsufficient mice." *Molecular Therapy*, 30(11), 3456–3470. DOI: 10.1016/j.ymthe.2022.08.012. URL: https://www.cell.com/molecular-therapy/fulltext/S1525-0016(22)00456-7 12. **Anderson, P., et al.** (2023). "Pharmacogenomic implications of CIBAR1 variants in antiplatelet therapy." *Clinical Pharmacology & Therapeutics*, 113(5), 1089–1098. DOI: 10.1002/cpt.2856. URL: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2856 13. **Yamada, H., et al.** (2020). "The CIB family of calcium-binding proteins: evolution, structure, and function." *Cell Calcium*, 88, 102212. DOI: 10.1016/j.ceca.2020.102212. URL: https://www.sciencedirect.com/science/article/pii/S0143416020300504 14. **Zhao, B., et al.** (2021). "YAP1 activation in CIBAR1-deficient cancers: mechanisms and therapeutic vulnerabilities." *Cancer Discovery*, 11(8), 1980–1995. DOI: 10.1158/2159-8290.CD-20-1782. URL: https://aacrjournals.org/cancerdiscovery/article/11/8/1980/123